Non-alcoholic steatohepatitis: Review of a growing medical problem

European Journal of Internal Medicine

Volumn 15, Issue 1, 2004, Pages 10-21

  Te Sligte, K ^a   Bourass, I ^a   Sels, J P ^a   Driessen, A ^a   Stockbrugger, R W ^a   Koek, G H ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Fatty liver; Free fatty acids; Insulin resistance; Oxidative stress; Pathogenesis; Therapy

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; AMIODARONE; ANTIVIRUS AGENT; ASCORBIC ACID; CALCIUM CHANNEL BLOCKING AGENT; CARBOHYDRATE; COCAINE; CYTOKINE; DIDANOSINE; ESTROGEN; FATTY ACID; FIALURIDINE; FREE RADICAL; GLUCOCORTICOID; INSULIN SENSITIZING AGENT; METFORMIN; METHOTREXATE; PERHEXILINE MALEATE; PHOSPHORUS; PIOGLITAZONE; ROSIGLITAZONE; SATURATED FATTY ACID; TAMOXIFEN; TETRACYCLINE; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; URSODEOXYCHOLIC ACID; VALPROIC ACID; ZIDOVUDINE;

ADIPOSE TISSUE; ANTIOXIDANT ACTIVITY; CALORIC INTAKE; CHRONIC HEPATITIS; CLINICAL FEATURE; CYTOKINE PRODUCTION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENTERITIS; EXERCISE; FATTY LIVER; FIBROSIS; HEMOCHROMATOSIS; HEPATITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERLIPOPROTEINEMIA TYPE 3; HYPERTENSION; INSULIN RESISTANCE; LIFESTYLE; LIPID PEROXIDATION; LIPODYSTROPHY; LIVER CELL; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER INJURY; LIVER TOXICITY; NONALCOHOLIC FATTY LIVER; OXIDATION; OXIDATIVE STRESS; PATHOGENESIS; POLYDIPSIA; PRURITUS; REVIEW; STEATOSIS; TUMOR NECROSIS; WEIGHT REDUCTION; WOLMAN DISEASE;

EID: 1842455276     PISSN: 09536205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejim.2003.12.008     Document Type: Review

References (115)

1. Ludwig J., Viggiano T.R., McGill D.B., Ott B.J. Nonalcoholic steatohepatitis. Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin. Proc. 55:1980 (July);434-438.
2. Angulo P. Nonalcoholic fatty liver disease. N. Engl. J. Med. 346(16):2002;1221-1231.
3. Clark J.M., Brancati F.L., Diehl A.M. Nonalcoholic fatty liver disease. Gastroenterology. 122(6):2002;1649-1657.
4. Marrero J.A., Fontana R.J., Su G.L., Conjeevaram H.S., Emick D.M., Lok A.S. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology. 36(6):2002;1349-1354.
5. Neuschwander Tetri B.A., Caldwell S.H. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology. 37(5):2003;1202-1219.
6. Reid A.E. Nonalcoholic steatohepatitis. Gastroenterology. 121(3):2001;710-723.
7. Chitturi S., Abeygunasekera S., Farrell G.C., Holmes Walker J., Hui J.M., Fung C.et al. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology. 35(2):2002;373-379.
8. Marchesini G., Bugianesi E., Forlani G., Cerrelli F., Lenzi M., Manini R.et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 37(4):2003;917-923.
9. Pagano G., Pacini G., Musso G., Gambino R., Mecca F., Depetris N.et al. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. Hepatology. 35(2):2002;367-372.
10. DeFronzo R.A. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidaemia and atherosclerosis. Neth. J. Med. 50(5):1997;191-197.
11. de Knegt R.J. Non-alcoholic steatohepatitis: clinical significance and pathogenesis. Scand. J. Gastroenterol. 234:2001;88-92. [Suppl.].
12. Youssef W.I., McCullough A.J. Steatohepatitis in obese individuals. Best practice and research. Clin. Gastroenterol. 16(5):2002;733-747.
13. Chitturi S., Farrell G., Frost L., Kriketos A., Lin R., Liddle C.et al. Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: a manifestation of lipotoxicity? Hepatology. 36(2):2002;403-409.
14. Bugianesi E., Leone N., Vanni E., Marchesini G., Brunello F., Carucci P.et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology. 123(1):2002;134-140.
15. Seidell J.C. Obesity, insulin resistance and diabetes - a worldwide epidemic. Br. J. Nutr. 83(Suppl. 1):2000;S5-S8.
16. Seidell J.C., Flegal K.M. Assessing obesity: classification and epidemiology. Br. Med. Bull. 53(2):1997;238-252.
17. Visscher T.L., Kromhout D., Seidell J.C. Long-term and recent time trends in the prevalence of obesity among Dutch men and women. Int. J. Obes. Relat. Metab. Disord. 26(9):2002;1218-1224.
18. Allison D.B., Fontaine K.R., Manson J.E., Stevens J., VanItallie T.B. Annual deaths attributable to obesity in the United States. JAMA. 282(16):1999;1530-1538.
19. Bender R., Trautner C., Spraul M., Berger M. Assessment of excess mortality in obesity. Am. J. Epidemiol. 147(1):1998;42-48.
20. Must A., Spandano J., Coakley E.H., Field A.E., Colditz G., Dietz W.H. The disease burden associated with overweight and obesity. JAMA. 282(16):1999;1523-1529.
21. Diehl A.M., Goodman Z., Ishak K.G. Alcohollike liver disease in nonalcoholics. A clinical and histologic comparison with alcohol-induced liver injury. Gastroenterology. 95(4):1988;1056-1062.
22. Bacon B.R., Farahvash M.J., Janney C.G., Neuschwander Tetri B.A. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology. 107(4):1994;1103-1109.
23. Powell E.E., Cooksley W.G., Hanson R., Searle J., Halliday J.W., Powell L.W. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology. 11(1):1990;74-80.
24. Lee R.G. Nonalcoholic steatohepatitis: a study of 49 patients. Hum. Pathol. 20(6):1989;594-598.
25. Tsushima Y., Endo K. Spleen enlargement in patients with nonalcoholic fatty liver: correlation between degree of fatty infiltration in liver and size of spleen. Dig. Dis. Sci. 45(1):2000;196-200.
26. Mehta K., Van Thiel D.H., Shah N., Mobarhan S. Nonalcoholic fatty liver disease: pathogenesis and the role of antioxidants. Nutr. Rev. 60(9):2002;289-293.
27. Sumida Y., Nakashima T., Yoh T., Furutani M., Hirohama A., Kakisaka Y.et al. Serum thioredoxin levels as a predictor of steatohepatitis in patients with nonalcoholic fatty liver disease. J. Hepatol. 38(1):2003;32-38.
28. Hasegawa T., Yoneda M., Nakamura K., Makino I., Terano A. Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study. Aliment. Pharmacol. Ther. 15(10):2001;1667-1672.
29. Joy D., Thava V.R., Scott B.B. Diagnosis of fatty liver disease: is biopsy necessary? Eur. J. Gastroenterol. Hepatol. 15(5):2003;539-543.
30. Saadeh S., Younossi Z.M., Remer E.M., Gramlich T., Ong J.P., Hurley M.et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology. 123(3):2002;745-750.
31. Jacobs J.E., Birnbaum B.A., Shapiro M.A., Langlotz C.P., Slosman F., Rubesin S.E.et al. Diagnostic criteria for fatty infiltration of the liver on contrast-enhanced helical CT. Am. J. Roentgenol. 171(3):1998;659-664.
32. Bravo A.A., Sheth S.G., Chopra S. Currents concepts: liver biopsy. N. Engl. J. Med. 344:2001;495-500.
33. Sonsuz A., Basaranoglu M., Ozbay G. Relationship between aminotransferase levels and histopathological findings in patients with nonalcoholic steatohepatitis. Am. J. Gastroenterol. 95(5):2000;1370-1371.
34. Mofrad P., Contos M.J., Haque M., Sargeant C., Fisher R.A., Luketic V.A.et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology. 37(6):2003;1286-1292.
35. Brunt E.M., Tiniakos D.G. Pathology of steatohepatitis. Best practice and research. Clin. Gastroenterol. 16(5):2002;691-707.
36. Brunt E.M., Janney C.G., Di Bisceglie A.M., Neuschwander Tetri B.A., Bacon B.R. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am. J. Gastroenterol. 94(9):1999;2467-2474.
37. Van Ness M.M., Diehl A.M. Is liver biopsy useful in the evaluation of patients with chronically elevated liver enzymes? Ann. Intern. Med. 111:1989;473-478.
38. Day C.P. Pathogenesis of steatohepatitis. Best practice and research. Clin. Gastroenterol. 16(5):2002;663-678.
39. Castro Cabezas M., Erkelens D.W., van Dijk H. Vrije vetzuren: mediatoren van insulineresistentie en atherosclerose. Ned. Tijdschr. Geneeskd. 146(3):2002;103-109.
40. Fruhbeck G., Gomez Ambrosi J., Muruzabal F.J., Burrell M.A. The adipocyte: a model for integration of endocrine and metabolic signaling in energy metabolism regulation. Am. J. Physiol., Endocrinol. Metab. 280(6):2001;E827-E847.
41. Haque M., Sanyal A.J. The metabolic abnormalities associated with non-alcoholic fatty liver disease. Best Pract. Res., Clin. Gastroenterol. 16(5):2002;709-731.
42. Parks E.J. Dietary carbohydrate's effects on lipogenesis and the relationship of lipogenesis to blood insulin and glucose concentrations. Br. J. Nutr. 87(Suppl. 2):2002;S247-S253.
43. Schwarz J.M., Linfoot P., Dare D., Aghajanian K. Hepatic de novo lipogenesis in normoinsulinemic and hyperinsulinemic subjects consuming high-fat, low-carbohydrate and low-fat, high-carbohydrate isoenergetic diets. Am. J. Clin. Nutr. 77(1):2003;43-50.
44. van Steenbergen W. Niet-alcoholische steatohepatitis: een oorzaak van levercirrose bij obesitas en diabetes mellitus. Tijdschr. Geneeskd. 55(20):1999;1419-1424.
45. Misra A., Vikram N.K. Clinical and pathophysiological consequences of abdominal adiposity and abdominal adipose tissue depots. Nutrition. 19(5):2003;457-466.
46. Shulman G.I. Cellular mechanisms of insulin resistance. J. Clin. Invest. 106(2):2000;171-176.
47. Arner P. The adipocyte in insulin resistance: key molecules and the impact of the thiazolidinediones. Trends Endocrinol. Metab. 14(3):2003;137-145.
48. Li Z., Yang S., Lin H., Huang J., Watkins P.A., Moser A.B.et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology. 37(2):2003;343-350.
49. Phillips S.A., Ciaraldi T.P., Kong A.P., Bandukwala R., Aroda V., Carter L.et al. Modulation of circulating and adipose tissue adiponectin levels by antidiabetic therapy. Diabetes. 52(3):2003;667-674.
50. Uysal K.T., Wiesbrock S.M., Marino M.W., Hotamisligil G.S. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature. 389:1997 (9 Oct.);610-614.
51. Cassader M., Gambino R., Musso G., Depetris N., Mecca F., Cavallo Perin P.et al. Postprandial triglyceride-rich lipoprotein metabolism and insulin sensitivity in nonalcoholic steatohepatitis patients. Lipids. 36(10):2001;1117-1124.
52. de Almeida I.T., Cortez Pinto H., Fidalgo G., Rodrigues D., Camilo M.E. Plasma total and free fatty acids composition in human non-alcoholic steatohepatitis. Clin. Nutr. 21(3):2002;219-223.
53. Musso G., Gambino R., De Michieli F., Cassader M., Rizzetto M., Durazzo M.et al. Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. Hepatology. 37(4):2003;909-916.
54. Sanyal A.J., Campbell Sargent C., Mirshahi F., Rizzo W.B., Contos M.J., Sterling R.K.et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology. 120(5):2001;1183-1192.
55. Charlton M., Sreekumar R., Rasmussen D., Lindor K., Nair K.S. Apolipoprotein synthesis in nonalcoholic steatohepatitis. Hepatology. 35(4):2002;898-904.
56. Bernard S., Touzet S., Personne I., Lapras V., Bondon P.J., Berthezene F.et al. Association between microsomal triglyceride transfer protein gene polymorphism and the biological features of liver steatosis in patients with type II diabetes. Diabetologia. 43(8):2000;995-999.
57. Sugden M.C., Orfali K.A., Holness M.J. The pyruvate dehydrogenase complex: nutrient control and the pathogenesis of insulin resistance. J. Nutr. 125(6 Suppl.):1995;1746s-1752s.
58. Benzie I.F. Lipid peroxidation: a review of causes, consequences, measurement and dietary influences. Int. J. Food Sci. Nutr. 47(3):1996;233-261.
59. Loguercio C., De Girolamo V., de Sio I., Tuccillo C., Ascione A., Baldi F.et al. Non-alcoholic fatty liver disease in an area of southern Italy: main clinical, histological, and pathophysiological aspects. J. Hepatol. 35(5):2001;568-574.
60. Lee C.H., Olson P., Evans R.M. Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors. Endocrinology. 144(6):2003;2201-2207.
61. Robertson G., Leclercq I., Farrell G.C. Nonalcoholic steatosis and steatohepatitis: II. Cytochrome P-450 enzymes and oxidative stress. Am. J. Physiol.: Gastrointest. Liver Physiol. 281(5):2001;G1135-G1139.
62. Tilg H., Diehl A.M. Cytokines in alcoholic and nonalcoholic steatohepatitis. N. Engl. J. Med. 343(20):2000;1467-1476.
63. Cortez Pinto H., Chatham J., Chacko V.P., Arnold C., Rashid A., Diehl A.M. Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis: a pilot study. JAMA. 282(17):1999;1659-1664.
64. Angulo P., Lindor K.D. Insulin resistance and mitochondrial abnormalities in NASH: a cool look into a burning issue. Gastroenterology. 120(5):2001;1281-1285.
65. Pessayre D., Mansouri A., Fromenty B. Nonalcoholic steatosis and steatohepatitis: V. Mitochondrial dysfunction in steatohepatitis. Am. J. Physiol.: Gastrointest. Liver Physiol. 282(2):2002;G193-G199.
66. Anzenbacher P., Anzenbacherova E. Cytochromes P450 and metabolism of xenobiotics. Cell. Mol. Life Sci. 58(5-6):2001;737-747.
67. Chalasani N., Gorski J.C., Asghar M.S., Asghar A., Foresman B., Hall S.D.et al. Hepatic cytochrome P450 2E1 activity in nondiabetic patients with nonalcoholic steatohepatitis. Hepatology. 37(3):2003;544-550.
68. Perlemuter G., Corre M.P., Conti M., Davit-Spraul A., Cosson C., Oppert J.M.et al. Increase of liver anti-oxidant enzyme activities in non-alcoholic steatohepatitis (NASH): a defense against an oxidative stress. [Abstract] J. Hepatol. 38(Suppl. 2):2003;199.
69. Sreekumar R., Rosado B., Rasmussen D., Charlton M. Hepatic gene expression in histologically progressive nonalcoholic steatohepatitis. Hepatology. 38(1):2003;244-251.
70. Lefkowitch J.H., Haythe J.H., Regent N. Kupffer cell aggregation and perivenular distribution in steatohepatitis. Mod. Pathol. 15(7):2002;699-704.
71. Susca M., Grassi A., Zauli D., Volta U., Lenzi M., Marchesini G.et al. Liver inflammatory cells, apoptosis, regeneration and stellate cell activation in non-alcoholic steatohepatitis. Dig. Liver Dis. 33(9):2001;768-777.
72. Diehl A.M. Nonalcoholic steatosis and steatohepatitis: IV. Nonalcoholic fatty liver disease abnormalities in macrophage function and cytokines. Am. J. Physiol.: Gastrointest. Liver Physiol. 282(1):2002;G1-G5.
73. Crespo J., Cayon A., Fernanadez Gil P., Hernandez Guerra M., Mayorga M., Dominguez Diez A.et al. Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. Hepatology. 34(6):2001;1158-1163.
74. Poli G. Pathogenesis of liver fibrosis: role of oxidative stress. Mol. Aspects Med. 21(3):2000;49-98.
75. Galli A., Crabb D.W., Ceni E., Salzano R., Mello T., Svegliati Baroni G.et al. Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro. Gastroenterology. 122(7):2002;1924-1940.
76. Paradis V., Perlemuter G., Bonvoust F., Dargere D., Parfait B., Vidaud M.et al. High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. Hepatology. 34(4 Pt. 1):2001;738-744.
77. Leclercq I.A., Farrell G.C., Schriemer R., Robertson G.R. Leptin is essential for the hepatic fibrogenic response to chronic liver injury. J. Hepatol. 37(2):2002;206-213.
78. Chitturi S., Weltman M., Farrell G.C., McDonald D., Liddle C., Samarasinghe D.et al. HFE mutations, hepatic iron, and fibrosis: ethnic-specific association of NASH with C282Y but not with fibrotic severity. Hepatology. 36(1):2002;142-149.
79. Clouston A.D., Powell E.E. Interaction of non-alcoholic fatty liver disease with other liver diseases. Best practice and research. Clin. Gastroenterol. 16(5):2002;767-781.
80. Fargion S., Mattioli M., Fracanzani A.L., Sampietro M., Tavazzi D., Fociani P.et al. Hyperferritinemia, iron overload, and multiple metabolic alterations identify patients at risk for nonalcoholic steatohepatitis. Am. J. Gastroenterol. 96(8):2001;2448-2455.
81. Mendler M.H., Turlin B., Moirand R., Jouanolle A.M., Sapey T., Guyader D.et al. Insulin resistance-associated hepatic iron overload. Gastroenterology. 117(5):1999;1155-1163.
82. Willner I.R., Waters B., Patil S.R., Reuben A., Morelli J., Riely C.A. Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency, and severity of disease. Am. J. Gastroenterol. 96(10):2001;2957-2961.
83. Valenti L., Fracanzani A.L., Dongiovanni P., Santorelli G., Branchi A., Taioli E.et al. Tumor necrosis factor alpha promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease. Gastroenterology. 122(2):2002;274-280.
84. Mensenkamp A.R., Havekes L.M., Romijn J.A., Kuipers F. Hepatic steatosis and very low density lipoprotein secretion: the involvement of apolipoprotein E. J. Hepatol. 35(6):2001;816-822.
85. Tremblay A. Physical activity and obesity. Bailliere's best practice and research. Clin. Endocrinol. Metab. 13(1):1999;121-129.
86. Stone N.J., Kushner R. Effects of dietary modification and treatment of obesity. Emphasis on improving vascular outcomes. Med. Clin. North Am. 84(1):2000;95-122.
87. Angulo P., Lindor K.D. Treatment of non-alcoholic steatohepatitis. Best practice and research. Clin. Gastroenterol. 16(5):2002;797-810.
88. Hardman A.E. Physical activity, obesity and blood lipids. Int. J. Obes. Relat. Metab. Disord. 23(Suppl. 3):1999;S64-S71.
89. Riccardi G., Rivellese A.A. Dietary treatment of the metabolic syndrome - the optimal diet. Br. J. Nutr. 83(Suppl. 1):2000;S143-S148.
90. Astrup A., Ryan L., Grunwald G.K., Storgaard M., Saris W., Melanson E.et al. The role of dietary fat in body fatness: evidence from a preliminary meta-analysis of ad libitum low-fat dietary intervention studies. Br. J. Nutr. 83(Suppl. 1):2000;S25-S32.
91. Facchini F.S., Hua N.W., Stoohs R.A. Effect of iron depletion in carbohydrate-intolerant patients with clinical evidence of nonalcoholic fatty liver disease. Gastroenterology. 122(4):2002;931-939.
92. Guma G., Viola L., Thome M., Galdame O., Alvarez E. Ursodeoxycholic acid in the treatment of non-alcoholic steatohepatitis: results of a prospective clinical controlled trial. [Abstract] Hepatology. 26(4 Pt. 2):1997;387A.
93. Ceriani R., Brunati S., Sacchi E., Colombo G. Effect of ursodeoxycholic acid plus diet in patients with non-alcoholic steatohepatitis. [Abstract] Hepatology. 28:1998;386A.
94. Bagci S., Uygun A., Kadayifci A., Bektas A., Ates Y., Erdil A.et al. Ursodeoxycholic acid in the treatment of nonalcoholic steatohepatitis. [Abstract] J. Hepatol. 38(Suppl. 2):2003;195.
95. Laurin J., Lindor K., Crippin J.S., Gossard A., Gores G.J., Ludwig J.et al. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study. Hepatology. 23(6):1996;1464-1467.
96. Mendez-Sanchez N., Gonzalez V., Pichardo-Bahena R., Uribe M. Weight reduction and ursodeoxycholic acid in subjects with nonalcoholic fatty liver disease: a double-blind, randomized, placebo-controlled trial. [Abstract] Hepatology. 36(4 Pt. 2):2002;412A.
97. Zangeneh F., Kudva Y.C., Basu A. Insulin sensitizers. Mayo Clin. Proc. 78(4):2003;471-479.
98. Marchesini G., Brizi M., Bianchi G., Tomassetti S., Zoli M., Melchionda N. Metformin in non-alcoholic steatohepatitis. Lancet. 358(9285):2001;893-894.
99. Uygun A., Isik A.T., Kadayifci A., Yesilova Z., Gulsen M., Karaeren N.et al. Metformin in the treatment of nonalcoholic steatohepatitis. [Abstract] J. Hepatol. 38(Suppl. 2):2003;195.
100. Oruc N., Dereli D., Yilmaz C., Yuce G., Gunsar F., Akarca U.S. Beneficial effects of insulin sensitizing agents on fatty liver disease; preliminary results. [Abstract] J. Hepatol. 38(Suppl. 2):2003;198.
101. Picard F., Auwerx J. PPAR (gamma) and glucose homeostasis. Annu. Rev. Nutr. 22:2002;167-197.
102. Tordjman J., Chauvet G., Quette J., Beale E.G., Forest C., Antoine B. Thiazolidinediones block fatty acid release by inducing glyceroneogenesis in fat cells. J. Biol. Chem. 278(21):2003;18785-18790.
103. Boden G., Cheung P., Mozzoli M., Fried S.K. Effect of thiazolidinediones on glucose and fatty acid metabolism in patients with type 2 diabetes. Metab. Clin. Exp. 52(6):2003;753-759.
104. Diamant M., Heine R. Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence. Drugs. 63(13):2003;1373-1405.
105. Neuschwander Tetri B.A., Brunt E.M., Wehmeier K.R., Sponseller C.A., Hampton K., Bacon B.R. Interim results of a pilot study demonstrating the early effects of the PPAR-gamma ligand rosiglitazone on insulin sensitivity, aminotransferases, hepatic steatosis and body weight in patients with non-alcoholic steatohepatitis. J. Hepatol. 38(4):2003;434-440.
106. Azuma T., Tomita K., Kato S., Adachi M., Inokuchi S., Kitamura N.et al. A pilot study of a thiazolidinedione, pioglitazone, in nonalcoholic steatohepatitis. [Abstract] Hepatology. 36(4 Pt. 2):2002;406A.
107. Yakaryilmaz F., Guliter S., Ozenirler O., Akyol G. Vitamin E treatment for patients with nonalcoholic steatohepatitis: results of a pilot study. [Abstract] J. Hepatol. 38(Suppl. 2):2003;203.
108. Sanyal A., Contos M.J., Stravitz R.T., Luketic V.A., Sterling R.K., Shiffman M.L.et al. A randomized controlled pilot study of pioglitazone and vitamin E versus vitamin E for nonalcoholic steatohepatitis. [Abstract] Hepatology. 36(4 Pt. 2):2002;382A.
109. Gulbahar O., Karasu Z.A., Ersoz G., Akarca U.S., Musoglu A. Treatment of non-alcoholic steatohepatitis with N-acetyl cystein. [Abstract] Gastroenterology. 118(4):2000;A1444.
110. Basaranoglu M., Acbay O., Sonsuz A. A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis. J. Hepatol. 31(2):1999;384.
111. Merat S., Malekzadeh R., Sohrabi M.R., Hormazdi M., Naserimoghadam S., Mikaeli J.et al. Probucol in the treatment of nonalcoholic steatohepatitis: an open-labeled study. J. Clin. Gastroenterol. 36(3):2003;266-268.
112. Abdelmalek M.F., Angulo P., Jorgensen R.A., Sylvestre P.B., Lindor K.D. Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study. Am. J. Gastroenterol. 96(9):2001;2711-2717.
113. Miglio F., Rovati L.C., Santoro A., Setnikar I. Efficacy and safety of oral betaine glucuronate in non-alcoholic steatohepatitis. A double-blind, randomized, parallel-group, placebo-controlled prospective clinical study. ArzneimittelForschung. 50(8):2000;722-727.
114. Harrison S.A., Ramrakhiani S., Brunt E.M., Anbari M.A., Cortese C., Bacon B.R. Orlistat in the treatment of NASH: a case series. Am. J. Gastroenterol. 98(4):2003;926-930.
115. Popescu A. Preliminary results of the treatment with an endothelin receptor antagonist (ET-RA) in patients with nonalcoholic steatohepatitis (NASH) associating metabolic disorders. [Abstract] J. Hepatol. 38(Suppl. 2):2003;199.